Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Completed 5Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Pancreatic Neoplasms 3Resectable Pancreatic Cancer 1Adenocarcinoma of the Pancreas 1Adenocarcinoma 1

Interventions

pembrolizumab 243Nivolumab 145Cyclophosphamide 135Cisplatin 134Paclitaxel 115Carboplatin 109Gemcitabine 99Radiotherapy 86Dexamethasone 84Docetaxel 80atezolizumab 69Ipilimumab 69Fluorouracil 60Blood Specimen Collection 60Doxorubicin 57Bevacizumab 57fludarabine 54Rituximab 54Oxaliplatin 52Surveys and Questionnaires 50Prednisone 50Lenalidomide 50Etoposide 49Standard of Care 46Capecitabine 46Cetuximab 45Trastuzumab 44Radiosurgery 44Magnetic Resonance Spectroscopy 44durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × paricalcitol × 1 year × Clear all
NCT03415854 2026-05-12

NABPLAGEMD

HonorHealth Research Institute

Phase 2 Completed
34 enrolled 11 charts
Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT03138720 2026-04-22

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

HonorHealth Research Institute

Phase 2 Completed
40 enrolled 22 charts
Gastrointestinal

Resectable Pancreatic Cancer

NCT04524702 2026-01-23

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

Emory University

Phase 2 Completed
10 enrolled 13 charts
Gastrointestinal

Pancreatic Neoplasms

NCT04054362 2025-11-21

PINBALL

Barts & The London NHS Trust

Phase 2 Completed
27 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02030860 2025-07-25

A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
15 enrolled
Gastrointestinal

Adenocarcinoma of the Pancreas

Data powered by HemOnc (CC BY 4.0) Colophon âš¡